The year 2021 began with governments racing to obtain, and administer, COVID-19 shots produced by some of the pharmaceutical industry’s biggest names, as well as new rivals from China and Russia. At stake: The ability of countries to protect their people and revive dormant economies, with the wealthiest nations quickly taking the lead. All along the way, Reuters correspondents around the world have provided deeply reported insight and exclusive stories into the progress achieved by early leaders in vaccines; the industry’s setbacks in producing shots at unprecedented scale; the unequal access that has left many countries behind; and the new variants that are upending expectations of what will happen next in this pandemic.
UNPARALLELED INSIGHT

• Living with COVID-19: Israel changes strategy as Delta variant hits
• Inside the race to find a COVID-19 pill
• Top scientists question the need for COVID-19 booster shots
• How a WHO push for global vaccines needed Europe
• How South Korea turbocharged specialty syringe production for COVID-19 vaccines
• How a coronavirus variant tore through an English island and onto the world stage
• Unthinkable? EU considers getting a vaccine boost from Russia’s Sputnik
• As vaccine nationalism deepens, governments pay to bring production home
• ‘When will it end?’: How a changing virus is reshaping scientists’ views on COVID-19
• Amid scramble for COVID-19 vaccine, Latin America turns to Russia
• Donors bet a U.S. firm could transform disease testing in Africa. Then COVID-19 hit
• Raging virus, few shots. How Brazil missed its chance to secure COVID-19 vaccines
• How U.S. CDC missed chances to spot COVID’s silent spread

EXCLUSIVE NEWS

• Sanofi offers to buy U.S. biotech, mRNA partner Translate Bio
• AstraZeneca COVID-19 vaccine shipped to Canada, Mexico before adequate plant inspections
• AstraZeneca exploring options for COVID-19 vaccine business
• European efforts to assess Russia’s Sputnik V vaccine stymied by data gaps
• S.Korea in talks with mRNA vaccine makers to make up to 1 bln doses
• In boost for Africa, Senegal aims to make COVID shots next year
• Pfizer begins to export U.S.-made COVID-19 vaccines, first to Mexico
• Fauci says U.S. may not need AstraZeneca COVID-19 vaccine

INDIA IN CRISIS

When the Delta variant emerged in India earlier this year, triggering a catastrophic wave of coronavirus cases, Reuters was ahead with exclusive news and insight, including:

• Health experts say India missed early alarm, let deadly coronavirus variant spread
• Death in the Himalayas: Poverty, fear, stretched resources propel India’s COVID crisis
• In COVID-hit India, a 26-year-old doctor decides who lives and who dies
• Indian scientists say, “We didn’t back double of vaccine dosing gap”
• India unlikely to resume sizable COVID-19 vaccine exports until October
• India delays big exports of AstraZeneca shot as infections surge
• From factory to faraway village: behind India’s mammoth vaccination drive
EYE ON THE STORY

• Reuters has produced insightful and engaging graphics. Highlights include:
  — COVID-19 Global Vaccine Tracker
  — Young, Indian, Unvaccinated: How the ‘world’s largest vaccination campaign’ faltered
  — Europe’s vaccine hesitancy
  — One in a million? Comparing the side effects and potential risks of the COVID-19 vaccines
  — Speed and trust: Keys to an effective vaccination program
  — From labs to jabs: The journey of COVID-19 vaccines from creation to inoculation

• Reuters award-winning photojournalism team has reported the story through vivid and moving pictures, including this pictures report on how one small Pennsylvania pharmacy is vaccinating thousands.

• Reuters has delivered comprehensive video coverage from all angles, including:
  — 70% of U.S. adults got at least one vaccine dose
  — WHO warns against mixing and matching COVID vaccines
  — Masks back on as Delta makes Israel change course
  — Rich countries aim to end vaccine inequities
  — Setbacks continue in Europe’s vaccine rollout
  — ‘Nobody is helping’: India’s hospitals in COVID crisis

TRUSTED VIEWS

Reuters Breakingviews offers unmatched, agenda-setting commentary. Here are some highlights:

• How UK’s vaccine taskforce did it
• Pfizer’s pandemic wealth produces ideal dealmaker
• Vaccine passports are a patchy travel fix
• Delta variant may make UK less of a virus outlier
• Vax surplus will be Uncle Sam’s hardest soft power
• Breakdown: Slaying virus Hydra is Herculean task
• MRNA is a $120 billion bet on platform, not vaccines

HOW TO ACCESS

• Source the multimedia news content you need with Reuters Connect.
• Access the latest stories online at reuters.com.
• Access market-leading events, reports and expert-driven content from Reuters Events.
• Get agenda-setting commentary from Reuters Breakingviews.
• Follow Reuters on Twitter and Facebook.

FOLLOW ALONG WITH REUTERS

Unlock more unrivaled coverage from Reuters and discover the latest editions of Reuters: The Big Picture.